Renal Cell Carcinoma MedDRA version: 14.0 Level: LLT Classification code 10038407 Term: Renal cell cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Conditions
Interventions
Product Name: Bay 73-4506 coprecipitate
Product Code: Bay 73-4506
Pharmaceutical Form: Tablet
INN or Proposed INN: n/a
CAS Number: n/a
Sponsors
Bayer HealthCare AG
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: •Male or female patients > 18 years of age. •Patients, who suffer from unresectable and/or metastatic, measurable predominantly clear cell RCC histologically or cytologically documented. Patients with rare subtypes of RCC such as pure papillary cell tumor, mixed tumor containing predominantly sarcomatoid cells, Bellini carcinoma, medullary carcinoma, or chromophobe oncocytic tumors are excluded from study participation. •Patients must be previously untreated for advanced disease. Prior palliative radiation therapy is allowed if the target lesion(s) are not included within the radiation field and no more than 30% of the bone marrow is irradiated. •Patients who have at least one uni-dimensional measurable lesion by CT-scan or MRI according to Response Evaluation Criteria in Solid Tumors (RECIST). •Patients with “Intermediate” or “Low” risk per the Motzer score. •Patients who have an Eastern Co-operative Oncology Group (ECOG) performance status of 0 or 1. •Adequate bone marrow, renal and hepatic function as assessed by the following laboratory requirements to be conducted within 7 days prior to study drug treatment: ?Total bilirubin 100000 /mm3, Hb > 9 g/dl, ANC > 1500/mm3 ?Alkaline phosphatase limit =65 years) yes F.1.3.1 Number of subjects for this age range 25
Exclusion criteria
Exclusion criteria: •Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis & T1] or any cancer curatively treated > 3 years prior to study entry. •Patients who have received prior systemic treatment regimens for RCC. Prior systemic therapy is defined as the following: a single chemotherapy agent (or regimen), a single immunotherapy agent (or regimen) or a single investigational treatment agent (or regimen), any anti-VEGF therapy (including bevacizumab, sunitinib and sorafenib) or any mTOR inhibitor therapy (including temsirolimus). Megestrol acetate or medroxyprogesterone, used as a single agent for the first line treatment of RCC will not constitute one prior systemic therapy. •Cardiac arrhythmias requiring anti-arrythmics (excluding beta blockers or digoxin), symptomatic coronary artery disease •History of cardiac disease or congestive heart failure >NYHA class 2. Patients must not have unstable angina (anginal symptoms at rest) or new-onset angina (began within the last 3 months) or myocardial infarction within the past 6 months •Uncontrolled hypertension defined as systolic blood pressure 150 mmHg or diastolic pressure 90 mmHg, despite optimal medical management. •Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy. •Active clinically serious infections (> grade 2 NCI-CTC version 3.0). •History of HIV infection or chronic hepatitis B or C. •Known history or symptomatic metastatic brain or meningeal tumours (head CT or MRI at screening to confirm the absence of CNS disease if patient has symptoms suggestive or consistent with CNS disease). •Patients with seizure disorder requiring medication (such as steroids or anti-epileptics). •History of organ allograft. •Patients with evidence or history of bleeding diasthesis. Any hemorrhage or bleeding event > CTCAE Grade 3 within 4 weeks of first dose of study. •Serious, non-healing wound, ulcer, or bone fracture. •Patients undergoing renal dialysis. •Substance abuse, medical, psychological or social conditions that may interfere with the patient’s participation in the study or evaluation of the study results. •Known or suspected allergy to the investigational agent or any agent given in association with this trial. •Any condition that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study. •Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and for at least 3 months after completion of study drug. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate. •Investigational drug therapy outside of this trial during or within 4 weeks of study entry •Prior exposure to the study drug. •Radiotherapy during study or within 3 weeks of start of s
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The objective of this study is to evaluate the antitumor activity and safety of BAY 73-4506 in previously untreated patients with metastatic or unresectable renal cell cancer (RCC). The primary efficacy endpoint of this study is listed in section 4.6.1. ;Secondary Objective: Secondary objectives include the evaluation of pharmacokinetic and biomarker data. The secondary endpoints of this trial are listed in sections 4.6.1 and 4.6.2.; Primary end point(s): The primary efficacy endpoint of this study is to evaluate the response rate of patients with advanced RCC to BAY 73-4506. Tumor response and disease progression will be evaluated based on RECIST tumor response criteria. Measurements will be made at baseline and then every 2 cycles (8 weeks- based on 28 day cycles) during the treatment period until progressive disease is documented, and also at the end of treatment visit if applicable. ; Timepoint(s) of evaluation of this end point: Measurements will be made at baseline and then every 2 cycles (8 weeks- based on 28 day cycles) during the treatment period until progressive disease is documented, and also at the end of treatment visit if applicable. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Secondary efficacy endpoints include overall survival, progression-free survival, time to progression, duration of response and duration of stable disease. ; Timepoint(s) of evaluation of this end point: Throughout the treatment period, the same lesions to those identified and measured at baseline must be evaluated using the same technique, the identical contrast agent and the same slice thickness. The body areas scanned at baseline should also continue to be scanned throughout the study. The exception to this is a baseline negative head CT/MRI if it was performed to rule out metastatic brain or meningeal tumours. | — |
Countries
Finland, France, Germany, Poland, United Kingdom, United States
Contacts
Public ContactBayer Clinical Trials Contact
Bayer HealthCare AG
Outcome results
None listed